DEXKETOPROFEN
Cognitive Change
Oregon Health and Science UniversitySmall moleculeEarly Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Cognitive Change cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Namenda UNC Lineberger Comprehensive Cancer Center | Phase 4 | BB |
DESVENLAFAXINE David Steffens | Phase 4 | BB |
Wellbutrin David Steffens | Phase 4 | BB |
Sertraline David Steffens | Phase 4 | BB |
Vortioxetine Brain and Cognition Discovery Foundation | Phase 2/3 | B |
View all 10 →
Same molecule, other indications
DEXKETOPROFEN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →